GLAXO vs RELIANCE
Head-to-head DCF comparison · GlaxoSmithKline Pharmaceuticals Limited vs Reliance Industries
Model Favors
GLAXO shows a larger model margin of safety
Leads on 3 of 4model metrics · not investment advice
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
Pharma
₹2,410
High RiskRELIANCE
Reliance Industries
Oil & Gas
₹1,364
Near Fair Value| Metric | GLAXO | RELIANCE |
|---|---|---|
| Verdict | High Risk | Near Fair Value |
| YieldIQ Score | 49/100 | 48/100 |
| Fair Value | ₹1,593 | ₹1,266 |
| Current Price | ₹2,410 | ₹1,364 |
| Margin of Safety | -33.9% | -7.2% |
| Moat | Narrow | Narrow |
| Piotroski F-Score | 8/9 | 6/9 |
| ROE | 47.5% | 6.9% |
| Debt / Equity | — | — |
| EV / EBITDA | 30.7× | 14.3× |
| Market Cap | ₹0.41 Lakh Cr | ₹18.46 Lakh Cr |
Run the full interactive analysis
DCF sliders, sensitivity tables, peer screens, watchlists — free to start.
Sign up free →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst.